TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35712943

Group type: EXPERIMENTAL
Intervention: Wheat grain moxibustion at Shixuan (EX‐UE 11) combined with rehabilitation training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine rehabilitation training
Number of subjects: 80
Study: 32449567

Group type: EXPERIMENTAL
Intervention: Bowel rest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35710445

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) for cooking
Number of subjects: 1854

Group type: COMPARATOR
Intervention: Usual cooking practices
Number of subjects: 1854
Study: 32861545

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 34246347

Group type: EXPERIMENTAL
Intervention: Ipatasertib (400 mg once daily) plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Placebo plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Ipatasertib-abiraterone
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Placebo-abiraterone
Number of subjects: 1101
Study: 33227624

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 34047723

Group type: EXPERIMENTAL
Intervention: Ketorolac group (received standard-of-care protocol, intravenous ketorolac at completion of procedure, and oral ketorolac on discharge)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (received standard-of-care pain protocol, including oxycodone-acetaminophen 5 to 325 mg on discharge)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Ketorolac group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ketorolac group and Control group
Number of subjects: 39
Study: 32311957

Group type: EXPERIMENTAL
Intervention: Yan Fu app for blood pressure management
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (no m-Health apps)
Number of subjects: 480
Study: 32623539

Group type: EXPERIMENTAL
Intervention: LEaP playgroup
Number of subjects: 71
Study: 34365104

Group type: EXPERIMENTAL
Intervention: LPC model (simplest model equivalent to logistic regression of histogram of individual percentage changes in seizure rate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional standard, median percent change (MPC)
Number of subjects: 0
Study: 32660564

Group type: EXPERIMENTAL
Intervention: sc-LCPUFA (1.19 g/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 35657463

Group type: EXPERIMENTAL
Intervention: Gem/Cis with DEBIRI
Number of subjects: 48

Group type: COMPARATOR
Intervention: Gem/Cis alone
Number of subjects: 48
Study: 32985373

Group type: EXPERIMENTAL
Intervention: Moovosity™ programme (8-week intervention)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait-list control (8-week wait)
Number of subjects: 34
Study: 33180910

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil supplementation for 4 weeks
Number of subjects: 0
Study: 36203486

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg Rimazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.4 mg/kg Rimazolam
Number of subjects: 100
Study: 33441871

Group type: EXPERIMENTAL
Intervention: EST-SSR markers identified from de novo transcriptome sequencing, with a total of 5,555 EST-SSRs identified from 35,251 unigenes.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cluster analysis based on EST-SSR data.
Number of subjects: 60
Study: 33092565

Group type: EXPERIMENTAL
Intervention: Upgraded Maternity Waiting Homes (MWHs) combined with local leader training on safe motherhood strategies
Number of subjects: 7593

Group type: EXPERIMENTAL
Intervention: Local leader training only
Number of subjects: 7593

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7593
Study: 34498987

Group type: EXPERIMENTAL
Intervention: Cognitive training for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received lectures on health and aging
Number of subjects: 0
Study: 34620410

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 8179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8179
Study: 35941573

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum probiotic (6 × 1010 CFUs) for 16 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 35
Study: 33545574

Group type: EXPERIMENTAL
Intervention: Compound Da-Cheng-Qi Decoction (CDCQD), 100 ml twice a day for 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plain boiled water (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Compound Da-Cheng-Qi Decoction (CDCQD)
Number of subjects: 30
Study: 33713247

Group type: EXPERIMENTAL
Intervention: 12-miRNA signature identified through NanoString nCounter miRNA assay
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: miRNA profiling
Number of subjects: 24
Study: 34000227

Group type: EXPERIMENTAL
Intervention: Islatravir 0.25 mg + doravirine (100 mg) + lamivudine (300 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Islatravir 0.75 mg + doravirine (100 mg) + lamivudine (300 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Islatravir 2.25 mg + doravirine (100 mg) + lamivudine (300 mg)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Doravirine (100 mg) + lamivudine (300 mg) + TDF (300 mg)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All islatravir groups combined
Number of subjects: 121

Group type: COMPARATOR
Intervention: Doravirine + lamivudine + TDF group
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Islatravir 2.25 mg group
Number of subjects: 121
Study: 36045091

Group type: EXPERIMENTAL
Intervention: Promoting healthier products on the Sainsbury's online supermarket platform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (standard products)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Banner clicks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy purchased
Number of subjects: 0
Study: 32985991

Group type: EXPERIMENTAL
Intervention: Digital app guidance for exercise (AP group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Physiotherapist guidance for exercise (PA group)
Number of subjects: 54
Study: 32962477

Group type: EXPERIMENTAL
Intervention: Liraglutide therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 33929379

Group type: EXPERIMENTAL
Intervention: Induction infliximab therapy
Number of subjects: 421
Study: 33266002

Group type: EXPERIMENTAL
Intervention: Cocoa and dark chocolate intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols
Number of subjects: 0
Study: 35836627

Group type: EXPERIMENTAL
Intervention: Combination of injection terlipressin 0.02 µg/kg/min infusion and injection norepinephrine 0.01 µg/kg/min infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Norepinephrine 0.01 µg/kg/min infusion alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of injection terlipressin and norepinephrine
Number of subjects: 50
Study: 33728989

Group type: EXPERIMENTAL
Intervention: HOPE (intervention)
Number of subjects: 225
Study: 33020137

Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Diagnostic arthroscopy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 210
Study: 37301833

Group type: EXPERIMENTAL
Intervention: COVID-19 period (n=542)
Number of subjects: 1072
Study: 33097306

Group type: EXPERIMENTAL
Intervention: Bio-electrical impedance vector analysis (BIVA)
Number of subjects: 183
Study: 32021090

Group type: EXPERIMENTAL
Intervention: SB4 autoinjector (AI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SB4 pre-filled syringe (PFS)
Number of subjects: 50
Study: 34224671

Group type: EXPERIMENTAL
Intervention: GP-led care
Number of subjects: 303

Group type: COMPARATOR
Intervention: Surgeon-led care
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: GP-led care with Oncokompas
Number of subjects: 303

Group type: COMPARATOR
Intervention: Surgeon-led care with Oncokompas
Number of subjects: 303
Study: 32381418

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium Hydroxide
Number of subjects: 0
Study: 35996199

Group type: EXPERIMENTAL
Intervention: TQG202 prophylaxis (30 ± 5 IU/kg initial dose for 24 weeks)
Number of subjects: 81
Study: 33920292

Group type: EXPERIMENTAL
Intervention: Caffeine (2 × 2.5 mg/kg/24 h)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 37
Study: 32652314

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IAIs) 2 mg every 4 weeks
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IAIs) 2 mg every 8 weeks after 3 initial monthly doses
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Ranibizumab every 4 weeks
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Eyes with predominantly classic CNV
Number of subjects: 1804

Group type: EXPERIMENTAL
Intervention: Eyes with occult CNV
Number of subjects: 1804
Study: 32610495

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DR7
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35032906

Group type: EXPERIMENTAL
Intervention: Lurasidone (20-80 mg/day)
Number of subjects: 271
Study: 34333555

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 21
Study: 32320100

Group type: EXPERIMENTAL
Intervention: Combination treatment (preoperative education, postoperative abdominal massage, and polyethylene glycol 4,000)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Preoperative education only
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination treatment and Preoperative education only
Number of subjects: 80
Study: 33583000

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (individual nutrition counseling) aiming for daily protein intake of 1.0-1.2 g/kg body weight, energy intake of 25-30 kcal/kg body weight/day, and serum vitamin D concentration ≥ 75 mmol/L
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (individual nutrition counseling)
Number of subjects: 1517
Study: 32067684

Group type: EXPERIMENTAL
Intervention: Experimental induction chemotherapy with two additional courses of topotecan, cyclophosphamide, and etoposide followed by standard induction chemotherapy (eight courses in total)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Standard induction therapy with six chemotherapy courses
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Experimental induction chemotherapy with two additional courses of topotecan, cyclophosphamide, and etoposide followed by standard induction chemotherapy
Number of subjects: 536
Study: 35162608

Group type: EXPERIMENTAL
Intervention: Tailored fall‐prevention program in addition to usual care
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care (exercise to prevent recurrent falls)
Number of subjects: 72
Study: 34656952

Group type: EXPERIMENTAL
Intervention: Skin roasted peanuts (SRP, 25 g/day)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Peanut butter (PB, 32 g/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control butter (CB, 32 g/day)
Number of subjects: 63
Study: 34077818

Group type: EXPERIMENTAL
Intervention: Adapted docetaxel regimen
Number of subjects: 325

Group type: COMPARATOR
Intervention: Standard docetaxel regimen
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Dose reduction of docetaxel
Number of subjects: 325
Study: 32299247

Group type: EXPERIMENTAL
Intervention: CBT‐Meno
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 36
Study: 34278653

Group type: EXPERIMENTAL
Intervention: Dove Real Beauty ID video
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 568
Study: 34155987

Group type: EXPERIMENTAL
Intervention: Main group with dysbiosis and hormonal imbalance
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group with significant number of lactobacilli
Number of subjects: 90
Study: 36735400

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily for 12 months)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo (once daily for 12 months)
Number of subjects: 252
Study: 33382436

Group type: EXPERIMENTAL
Intervention: Self-Care Ability (SCA) intervention
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Loneliness assessment
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Social isolation assessment
Number of subjects: 170
Study: 32527268

Group type: EXPERIMENTAL
Intervention: Real dual‐tDCS (2 mA for 20 mins) with concurrent paretic hand exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham dual‐tDCS
Number of subjects: 18
Study: 36273181

Group type: EXPERIMENTAL
Intervention: Jiu‐Wei‐Xi‐Feng granules (Os Draconis replaced by Concha Ostreae) (JWXFD)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Jiu‐Wei‐Xi‐Feng granules (original formula) (JWXFO)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: JWXFD
Number of subjects: 288
Study: 34294808

Group type: EXPERIMENTAL
Intervention: NK cells with K562 tumor cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NK cells with IL-15-secreting variant of K562 tumor cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: NK cells without tumor cells
Number of subjects: 0
Study: 32466854

Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000-unit pearl weekly for 4 weeks prior to the operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36056401

Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion-focused program
Number of subjects: 72
Study: 34653566

Group type: EXPERIMENTAL
Intervention: Intelligent insole system with pressure-sensing insoles and digital watch, worn during all daily activity for 18 months.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CG) without the intelligent insole system.
Number of subjects: 46
Study: 33136871

Group type: EXPERIMENTAL
Intervention: Surgical Procedure A (Carstens' variant with modifications)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Surgical Procedure B
Number of subjects: 291
Study: 35560498

Group type: EXPERIMENTAL
Intervention: HEAT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: EX
Number of subjects: 31

Group type: COMPARATOR
Intervention: CON
Number of subjects: 31
Study: 32980772

Group type: EXPERIMENTAL
Intervention: 20-Hz repetitive transcranial magnetic stimulation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 52
Study: 616744333

Group type: EXPERIMENTAL
Intervention: Vitamin B1 and B2 levels in ICP patients (Group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Total cholesterol levels in ICP patients (Group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LDL levels in ICP patients (Group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: HDL levels in ICP patients (Group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Triglycerides (TG) levels in ICP patients (Group 1)
Number of subjects: 75
Study: 35193445

Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy (twice-daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard physiotherapy (once-daily)
Number of subjects: 40
Study: 33433575

Group type: EXPERIMENTAL
Intervention: 45 mg sodium nitrite
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: 60 mg sodium nitrite
Number of subjects: 1502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1502
Study: 32689969

Group type: EXPERIMENTAL
Intervention: Half-Perc technique
Number of subjects: 240
Study: 36104235

Group type: EXPERIMENTAL
Intervention: 25 mg/day of empagliflozin
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 mg/day of empagliflozin
Number of subjects: 100
Study: 33097945

Group type: EXPERIMENTAL
Intervention: Exercise at 35% V̇O2 peak
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise at 50% V̇O2 peak
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise at 65% V̇O2 peak
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise at 80% V̇O2 peak
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-exercise at 65% V̇O2 peak
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Post-exercise at 80% V̇O2 peak
Number of subjects: 9
Study: 32475246

Group type: EXPERIMENTAL
Intervention: GTS stem
Number of subjects: 50

Group type: COMPARATOR
Intervention: Taperloc stem
Number of subjects: 50
Study: 33901728

Group type: EXPERIMENTAL
Intervention: Training workshop on early recognition and care for toddlers with ASD and use of webM-CHAT-R/F
Number of subjects: 46
Study: 33009281

Group type: EXPERIMENTAL
Intervention: Topical bromfenac (Yellox)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Combination treatment (bromfenac and dexamethasone)
Number of subjects: 722
Study: 32138641

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 15 °C (CW15)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cold water immersion at 8 °C (CW8)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Passive recovery (PAS)
Number of subjects: 29
Study: 32819209

Group type: EXPERIMENTAL
Intervention: Large poster depicting a natural woodland scene
Number of subjects: 0

Group type: COMPARATOR
Intervention: No poster (control condition)
Number of subjects: 0
Study: 33150227

Group type: EXPERIMENTAL
Intervention: HIV/AIDS knowledge assessment through a self‐administered questionnaire
Number of subjects: 200
Study: 36126605

Group type: EXPERIMENTAL
Intervention: Cetuximab plus radiotherapy (cet+RT)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Cisplatin plus radiotherapy (cis+RT)
Number of subjects: 407
Study: 32914276

Group type: EXPERIMENTAL
Intervention: EDOF Tecnis Symfony (ZXR00) IOL
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diffractive multifocal Tecnis + 2.75 D (ZKB00) IOL
Number of subjects: 29
Study: 36029467

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 33448029

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA‐IM)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 605
Study: 33058961

Group type: EXPERIMENTAL
Intervention: BMI > 30
Number of subjects: 5623

Group type: EXPERIMENTAL
Intervention: Per log ng/mL higher serum leptin
Number of subjects: 5623

Group type: COMPARATOR
Intervention: Reference BMI (BMI 18−25 kg/m2)
Number of subjects: 5623
Study: 35567859

Group type: EXPERIMENTAL
Intervention: Daily 100 mg aspirin
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 34764381

Group type: EXPERIMENTAL
Intervention: Scheduled bloodlettings
Number of subjects: 33

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COC)
Number of subjects: 33
Study: 33381574

Group type: EXPERIMENTAL
Intervention: Developed insoles with a toe-grip bar
Number of subjects: 12

Group type: COMPARATOR
Intervention: General insoles
Number of subjects: 12
Study: 35552971

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33459517

Group type: EXPERIMENTAL
Intervention: Operating room noise levels
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Physiological effects of noise
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Psychological effects of noise
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Overall effects of noise
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Noise disturbance score
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Non-affected staff
Number of subjects: 92
Study: 36249182

Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention through an app on a recycled mobile device for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard physiotherapy care recommended for patients discharged from the hospital
Number of subjects: 60
Study: 33849097

Group type: EXPERIMENTAL
Intervention: Multi-dimensional postpartum visits (MDPV)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine postpartum visits (Control)
Number of subjects: 114
Study: 34807249

Group type: EXPERIMENTAL
Intervention: Treatment group informed about 17 Japanese family policy benefits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no information exposure
Number of subjects: 0
Study: 32073874

Group type: EXPERIMENTAL
Intervention: 5 mL V. odorata syrup every 12 hours for 4 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: 5 mL placebo syrup every 12 hours for 4 weeks
Number of subjects: 83
Study: 35915032

Group type: EXPERIMENTAL
Intervention: Real-time visualization of CPR activity on a feedback device (Group C)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CPR checklist (Group B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No performance aid (Group A)
Number of subjects: 46
Study: 34628695

Group type: EXPERIMENTAL
Intervention: Non-viable Lactobacillus reuteri DSM17648
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 32609186

Group type: EXPERIMENTAL
Intervention: NF/AC
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: NA/AC
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: NF/PN
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: NA/PN
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 108
Study: 36446551

Group type: EXPERIMENTAL
Intervention: Use of an app to change dietary behaviour for IBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet or medication
Number of subjects: 0
Study: 32885846

Group type: EXPERIMENTAL
Intervention: Biologic therapy
Number of subjects: 2094

Group type: COMPARATOR
Intervention: Control group (RCT eligible patients)
Number of subjects: 2094
Study: 32389195

Group type: EXPERIMENTAL
Intervention: Hand hygiene compliance
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Glove use compliance
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Disinfection of reusable equipment compliance
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Waste management compliance
Number of subjects: 734